The FDA-approved anti-CD19 CAR-T cell treatments, tisagenelcleucel for the treatment of acute lymphoblastic leukemia (ALL) and axicabtagene ciloleucel for patients with lymphomas, are prime examples of the efficacy of CAR-T cell therapy in cancer treatment. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.